Apollo Commercial Real Estate Finance reports Q1 2026 results on April 29 with its dividend strength standing as the clearest point of differentiation — while short sellers have quietly rebuilt positions through April even as the stock has recovered.
The dividend score ranks in the 88th percentile universe-wide, the highest factor reading in the snapshot by a wide margin. That matters for a mortgage REIT trading at 0.92x book value — investors are essentially being paid to wait, with a dividend yield implied near 8.1%. The price-to-book has expanded roughly five points over the past month, signalling a modest but real re-rating. EPS momentum tells a weaker story: the 30-day reading ranks in just the 8th percentile, flagging that near-term earnings estimate revisions have been running negative.
Short interest has climbed sharply since mid-March, rising roughly 28% in a month to 3.9% of the free float — still a modest absolute level, but the direction of travel is worth noting. The build accelerated through late March and has held near current levels for most of April. Borrow conditions remain genuinely loose: cost to borrow has eased to around 0.45%, down from above 0.65% in late March, and availability is wide, meaning there is no squeeze pressure in the lending market. Options positioning is structurally elevated — a put/call ratio above 2.19 is striking in isolation, but it is actually slightly below the 20-day average of 2.21, making it a persistent feature of how this stock trades rather than a fresh defensive signal.
The analyst debate centres on credit quality versus portfolio growth. The bull case points to an 8.2% quarter-on-quarter expansion in the committed loan portfolio to $7.7 billion and the expectation that earnings per share will eventually exceed dividend levels, opening the door to a potential distribution increase. Bears counter that the externally managed structure limits accountability, and that rising commercial real estate stress — particularly if interest rates stay elevated — could push borrowers toward principal impairment, directly threatening book value and dividend sustainability. The most recent analyst action on record was Keefe, Bruyette & Woods raising its target to $11.50 in February while keeping an Outperform rating; JP Morgan had upgraded to Overweight and raised targets in late 2025. Both moves put the mean target around $11.63, modestly above the current $11.06 price, but those figures are now two to six months old and should be treated as directional rather than precise. The stock has recovered 6% over the past month, so the gap to target has narrowed.
The print will test whether portfolio growth is translating into distributable earnings that genuinely cover the dividend — and whether credit quality in the transitional lending book has held through a turbulent first quarter for commercial real estate.
See the live data behind this article on ORTEX.
Open ARI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
